Erratum
During the editorial process preceding the publication of this article an error was introduced in the heading of “Table 1 Univariate and multivariate analysis of elafin-positive cells in breast cancer patients.” This error was only noticed after publication of the final version. Specifically, both data-containing columns are labeled “Elafin Negative.” The data-containing column on the right should in fact be labeled “Elafin Positive (n = 482).” The corrected version can be found here (Table 1). Table 1 has also been updated in the original article to reflect the correct labeling of the columns.
Table 1.
Univariate and multivariate analysis of elafin-positive cells in breast cancer patients
| A. Univariate analysis, breast cancer (n = 793) | ||||
|---|---|---|---|---|
| Factors | Elafin negative (n = 311) | Elafin positive (n = 482) | p-value | |
| Age of diagnosis, year | 0.02 | |||
| Mean | 55.5 | 53.5 | ||
| Median (range) | 55 (26–86) | 52 (25–87) | ||
| Stage | <0.0001 | |||
| I | 120 (38.7) | 115 (24.0) | ||
| IIA | 128 (41.3) | 241 (50.2) | ||
| IIB | 62 (20.0) | 124 (25.8) | ||
| Unknown | 1 | 2 | ||
| ER | <0.0001 | |||
| Positive | 266 (85.5) | 280 (58.3) | ||
| Negative | 45 (14.5) | 200 (41.7) | ||
| Unknown | 0 | 2 | ||
| PR | <0.0001 | |||
| Positive | 218 (70.1) | 236 (49.2) | ||
| Negative | 93 (29.9) | 244 (50.8) | ||
| Unknown | 0 | 2 | ||
| HER-2 | 0.013 | |||
| Positive | 42 (13.5) | 98 (20.4) | ||
| Negative | 269 (86.5) | 383 (79.6) | ||
| Unknown | 0 | 1 | ||
| Grade | <0.0001 | |||
| I | 41 (14.2) | 31 (6.8) | ||
| II | 186 (64.6) | 197 (43.5) | ||
| III | 61 (21.2) | 225 (49.7) | ||
| Unknown | 23 | 29 | ||
| Tumor subtype | <0.0001 | |||
| Luminal A | 185 (61.9) | 158 (33.1) | ||
| Luminal B | 45 (15.1) | 94 (19.8) | ||
| Her2 positive | 42 (14.0) | 98 (20.7) | ||
| Triple negative | 27 (9.0) | 125 (26.4) | ||
| Unknown | 12 | 7 | ||
| Recurrence | <0.0001 | |||
| No | 250 (80.9) | 298 (62.3) | ||
| Yes | 59 (19.1) | 180 (37.7) | ||
| Unknown | 2 | 4 | ||
| B. Multivariate Cox proportional hazards analysis of clinicopathologic variables’ influence on breast cancer RFS in whole cohort (n = 793) | ||||
| Factor | HR | Se | P | 95% CI |
| Stage | ||||
| I | referent | |||
| IIA | 1.67 | 0.31 | 0.005 | 1.17-2.39 |
| IIB | 2.41 | 0.47 | <0.0001 | 1.65-3.52 |
| Age | 0.98 | 0.01 | <0.0001 | 0.97-0.99 |
| Elafin Positive | 1.94 | 0.3 | <0.0001 | 1.44-2.62 |
Footnotes
The online version of the original article can be found under doi:10.1186/s13058-014-0497-4.
Contributor Information
Joseph A Caruso, Email: tcaruso@mdanderson.org.
Cansu Karakas, Email: ckarakas@mdanderson.org.
Jing Zhang, Email: jzhang@mdanderson.org.
Min Yi, Email: myi@mdanderson.org.
Constance Albarracin, Email: calbarra@mdanderson.org.
Aysegul Sahin, Email: asahin@mdanderson.org.
Melissa Bondy, Email: mbondy@bcm.edu.
Jinsong Liu, Email: jliu@mdanderson.org.
Kelly K. Hunt, Email: khunt@mdanderson.org
Khandan Keyomarsi, Email: kkeyomar@mdanderson.org.
References
- 1.Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, et al. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Canc Res. 2014;16:3417. doi: 10.1186/s13058-014-0497-4. [DOI] [PMC free article] [PubMed] [Google Scholar]